Nextrials Collaborates with Industry Leaders to Expand Usage of Electronic Data to Better Initiate and Manage Clinical Trials
The flexibility of Nextrials’ Prism® enables seamless integration with key vendors’ IVR, central lab and drug distribution components
San Ramon, CA -- June 20, 2005 -- Nextrials, Inc., a leader in clinical research software and services, today announced that its flagship Prism software has been successfully integrated with products and services offered by some of the industry's premier vendors. In working with companies such as Dynarand, Covance, Cardinal Health, Fisher Clinical Services and AccuLogix, Nextrials has leveraged Prism's flexibility to deliver custom-tailored services to sponsors with specific requirements for achieving the rapid initiation and accurate management of clinical trials.
One of the most advanced Electronic Data Capture (EDC) products on the market, Prism now seamlessly integrates with other industry offerings in three key areas: interactive voice response (IVR), central lab and drug distribution. By enabling outside vendors to access Prism via a secure, encrypted Internet connection, real-time data can be collected and collapsed into a single, centralized system. This provides a sponsor with a more accurate snapshot of an ongoing clinical trial, regardless of its size or the number of test sites, and eases related trial management activities such as drug inventory and supply.
GlobeImmune, Inc., a biopharmaceutical company in Denver, CO, is one of many sponsors currently using Prism's advanced features integrated with those of a specialized vendor to facilitate external data transfers. For GlobeImmune, Nextrials collaborated with Covance to enable delivery of central lab data using CDISC, a new, platform-independent clinical data transfer standard recently developed by the Clinical Data Interchange Standards Consortium.
"An integrated EDC product such as Prism makes the process of managing clinical trials easier and more cost-effective, especially when it interfaces with -- and manages -- disparate components under a single umbrella," said John Ferraro, associate director of clinical operations for GlobeImmune. "Its ability to accept external data transferred under the new CDISC standard gives our researchers improved access to real-time data and valuable insight into the status of a drug in development."
"Nextrials was quick to recognize that there is a need within the industry to go beyond EDC to determine what else can be done with centralized data," said Anthony J. Costello, co-founder and vice president of product development and data services for Nextrials. "The ability to seamlessly integrate data from all partners in a clinical trial is a critical component of any worthwhile EDC system. Prism's feature set has been designed with CDISC in mind so that all data sources can be reliably combined into a complete central data warehouse worthy of ongoing study analysis."
Visitors can view live demonstrations of Prism at Nextrials' booths at the BIO 2005 Annual International Conference, being held at the Pennsylvania Convention Center in Philadelphia June 19-22 (booth #2651) and at the Drug Information Association's 41st Annual Meeting, being held at the Washington Convention Center in Washington, DC June 26-29 (booth #1851).
About Nextrials, Inc.
Founded by pharmaceutical researchers in 1999, Nextrials Innovates for Life by offering today's most novel products and services for speeding the delivery of life-saving drugs and medical devices to market. Prism, its award-winning Electronic Data Capture (EDC) solution, has been used at over 200 research sites to streamline the initiation and management of clinical trials. The company is headquartered in the San Francisco Bay area. For more information, visit www.nextrials.com or call 925-355-3000.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Phase III SELECT-GCA Trial Results Lead to FDA Approval of Rinvoq for Giant Cell Arteritis
April 30th 2025Rinvoq (upadacitinib) becomes the first oral JAK inhibitor approved by the FDA for the treatment of giant cell arteritis in adults, following robust data from the Phase III SELECT-GCA trial demonstrating its efficacy in achieving sustained remission and reducing glucocorticoid exposure.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
